E-602 drug page Clinical trials

Trials with E-602

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

1Trials
0Recruiting
1Countries
69Planned patients

Showing 1–1 of 1

Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
Finished Phase 1 69 patients NCT05259696

This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.

United States Feb 2022 – Oct 2024 Interventional
Combined with: Cemiplimab